Loading...
Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosis
In May 2019, China National Medical Products Administration approved the marketing of an elosulfase alfa injection (brand name: Vimizim) from BioMarin Pharmaceutical for the treatment of patients with mucopolysaccharidosis (MPS) type IVA. This is the first drug to treat MPS in China, and it has ende...
Na minha lista:
| Udgivet i: | Intractable Rare Dis Res |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6743428/ https://ncbi.nlm.nih.gov/pubmed/31523593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2019.01090 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|